Results 161 to 170 of about 39,211 (299)

Application and Research Progress of Nucleic Acid‐Based Drug Delivery Systems in the Treatment of Intracerebral Hemorrhage

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
This review summarizes recent advances in NADDS for treating ICH, highlighting the advantages and applications of key delivery technologies including lipid nanoparticles, exosomes, and DNA nanostructures. ABSTRACT Intracerebral hemorrhage (ICH) is a devastating stroke subtype associated with high mortality and neurological disability, yet effective ...
Jingyan Wang   +4 more
wiley   +1 more source

PHARMWATCH: A Proposed Multilayer Pharmacogenomics Framework for Contextual Star Allele Interpretation. [PDF]

open access: yesClin Transl Sci
ABSTRACT The Clinical Pharmacogenetics Implementation Consortium (CPIC) bases its drug‐gene recommendations on the assignment of star alleles, which map known genotypes to defined functional categories and corresponding drug dosage guidelines. The star allele framework, first proposed in 1996 for the CYP gene family and later formalized with CPIC's ...
Eisenhart C, Brickey R, Mewton J.
europepmc   +2 more sources

Shaping the Future of Pharmacology Education: Emerging Directions and International Initiatives From the Seventh International Union of Basic and Clinical Pharmacology Education Satellite Meeting

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 6, December 2026.
ABSTRACT The 7th International Union of Basic and Clinical Pharmacology Education Section (IUPHAR‐Ed) Satellite Meeting, held in conjunction with the 20th World Congress of Basic and Clinical Pharmacology in Melbourne, Australia, brought together 99 educators from 18 countries to share innovations and scholarship in pharmacology education.
Clare Guilding   +13 more
wiley   +1 more source

Pharmacogenomics in the United Arab Emirates: advances in population genomics and challenges in clinical implementation. [PDF]

open access: yesFront Pharmacol
Haitamar A   +6 more
europepmc   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2575-2584, 15 November 2026.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang   +9 more
wiley   +1 more source

Obstetric pharmacogenomics. [PDF]

open access: yesJ Basic Clin Physiol Pharmacol
Eke AC.
europepmc   +1 more source

ANK1 and EPB41 Variants and The Risk of Glucocorticoid‐Induced Osteonecrosis

open access: yesArthritis &Rheumatology, Volume 78, Issue 11, Page 2378-2389, November 2026.
Objective Steroid‐induced osteonecrosis of the femoral head (SONFH) is a refractory skeletal disorder influenced by genetic and environmental factors. However, conclusive pathogenic genetic evidence remains elusive due to the limited exploration of rare damaging variants. In this study, we aimed to identify rare variants associated with SONFH.
Shengbao Chen   +21 more
wiley   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3902-3913, November 2026.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy